Loading...
•
Sep 30, 2020
Denali Therapeutics Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020 and provided business highlights.
Key Takeaways
Denali Therapeutics reported a net loss of $58.2 million for the third quarter ended September 30, 2020. They commenced a collaboration with Biogen and completed patient enrollment in Cohort A for ETV:IDS (DNL310) Phase 1/2 in Hunter syndrome. The company's cash, cash equivalents, and marketable securities were $981.5 million as of September 30, 2020.
Commenced Biogen collaboration, receiving $560.0 million in upfront payments and potential for $1.125 billion in milestone payments plus profit sharing and royalties for the LRRK2 program.
Completed patient enrollment in Cohort A for ETV:IDS (DNL310) Phase 1/2 in Hunter syndrome, with early safety and biomarker data expected by year end 2020.
Highlighted potential of TV-enabled biotherapeutics portfolio at R&D Day, showcasing new preclinical data from ETV, PTV, ATV and OTV programs.
Entered collaboration with Secarna Pharmaceuticals to develop novel ASO therapeutics using Denali’s Oligonucleotide TV technology.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...